



Financial Tear Sheet

Corporate Profile

Ra Pharma® is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system.

Primary IR Contact

Jennifer Robinson

Phone: 617-674-9873

E-mail:

jrobinson@rapharma.com

Stock Performance

RARX (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$5.96**

Change (%) ▼
0.09 (1.49%)

Volume 229,499

52 Week Low \$4.78

Market Cap \$195,334,438

Rolling EPS -2.41

PE Ratio 0



Shares Outstanding 32,286,684

Data as of April 24, 2018 4:00 p.m. ET

Recent Headlines & Events

April 18, 2018 - 7:00 a.m.

[Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer](#)

There are currently no events scheduled.

March 14, 2018 - 4:15 p.m.

[Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update](#)

March 7, 2018 - 7:00 a.m.

[Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference](#)

Analyst Estimates / Ratings

Mean Recommendation: **1.8**

Unable to fulfill request.



Sell

Strong Buy

SEC Filings

Corporate Governance

Filing Date	Form
04/23/18	3
03/14/18	10-K

Robert Heft
Director

03/02/18

SC 13D/A

Jason Lettmann
Director

02/27/18

SC 13D/A

Ed Mathers
Director

Tim Pearson
Director

Rajeev Shah
Director

Peter Tuxen-Bisgaard
Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	107	235.67	83.2	26,875,807
Mutual Fund	118	25.45	10.0	3,212,218
Insider *	2	26.11	6.9	2,235,854

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
New Enterprise Associates (NEA)	5,490,073	17.0	1,996,437	February 16, 2018
RA Capital Management, LLC	3,851,808	11.9	2,500,000	February 14, 2018
Wellington Management Company, LLP	2,767,243	8.6	474,202	December 31, 2017
Morgenthaler Ventures	2,745,846	8.5	2,745,846	October 25, 2016
Novartis AG	1,615,996	5.0	-636,161	December 31, 2017
Novo Holdings A/S	1,531,562	4.7	-500,000	February 26, 2018
Plain (Plain)	1,320,657	4.1	1,320,657	October 25, 2016
Lightstone Ventures, L.P.	1,320,655	4.1	1,320,655	December 31, 2016
BlackRock Institutional Trust Company, N.A.	805,488	2.5	308,811	December 31, 2017

Rock Springs Capital Management LP	600,000	1.9	0	December 31, 2017
------------------------------------	---------	-----	---	-------------------

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)